diabetic foot ulcers (2,3). Fedorko et al. (1) claim that their study population is similar to that of Löndahl et al. (4) . This is not correct, as that study population was older; had a longer diabetes duration, a minimum ulcer duration of 3 months, a longer prespecified minimum prestudy period in a diabetic foot ulcer clinic; and had more comorbidities and higher rates of previous amputation (almost 50 vs. 6%) and previous vascular surgical intervention (55 vs. 12%) at baseline. Further, a mean age of 61 years is notably low (lower than the median age in European diabetic foot ulcer clinics), and there were notably many current smokers (55%).
Further, Fedorko et al. (1) No data about peripheral vascular circulation were given by Fedorko et al. Transcutaneous oxygen pressure measurement (TcPO 2 ) is commonly used to select and evaluate patients before, during, and after HBOT (2, 5) .
The span in ulcer duration (28-3,650 days), combined with the 12-weekoutcome end point where one-fourth of the study population was recommended for major amputation and one-fifth was healed, suggests a heterogeneous study population and that prestudy treatment applying international treatment guidelines might have been too short to select a robust hard-to-heal study population. Are the data normally distributed?
The "bubble" theory by which Fedorko et al. (1) dismiss the previous two doubleblind, randomized controlled trials seems irrelevant, and this harsh statement is of no value until its clinical relevance has been confirmed.
The International Working Group on the Diabetic Foot does not consider the trial by Duzgun et al. as justification for HBOT (3) .
We agree with the authors that more studies are needed to identify patients that might benefit from HBOT, but unfortunately this study contributes little to this; worse, its conclusion is not justified by the data presented.
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